Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma by Murphy, N C et al.
Expression of LMO4 and outcome in pancreatic ductal
adenocarcinoma
NC Murphy
1,2, CJ Scarlett
1, JG Kench
1,3, EYM Sum
4, D Segara
1, EK Colvin
1, J Susanto
1, PH Cosman
1, C-S Lee
2,5,
EA Musgrove
1, RL Sutherland
1, GJ Lindeman
4, SM Henshall
1, JE Visvader
4 and AV Biankin*,1,6
1Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia;
2Department of Anatomical Pathology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, New South Wales 2050, Australia;
3Institute
of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales 2145, Australia;
4The Walter and Eliza Hall Institute
of Medical Research, Parkville, Victoria 3050, Australia;
5Department of Pathology, University of Sydney, New South Wales 2006, Australia;
6Division
of Surgery, Bankstown Hospital, Eldridge Road, Bankstown, Sydney, New South Wales 2200, Australia
Identification of a biomarker of prognosis and response to therapy that can be assessed preoperatively would significantly improve
overall outcomes for patients with pancreatic cancer. In this study, patients whose tumours exhibited high LMO4 expression had a
significant survival advantage following operative resection, whereas the survival of those patients whose tumours had low or no
LMO4 expression was not significantly different when resection was compared with operative biopsy alone.
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Pancreatic cancer (PC) remains the fourth leading cause of
cancer death in western societies with a 5-year survival rate
of less than 5%. Pancreatectomy is the only therapeutic interven-
tion that can increase long-term survival. However, only 10–20%
of patients who undergo pancreatectomy survive for more than
3 years, and there is no method to predict preoperatively as
to which patients will benefit from resection (Yeo et al, 1997).
For the majority of patients who are unsuitable for operative
resection, non-operative approaches, including chemotherapy
and chemoradiotherapy, have met with limited success. To date,
there are no molecular markers of clinical utility, or rationally
designed, molecularly targeted therapies, for PC. Thus, there is
a crucial need for the identification of novel molecules important
in PC that may also have diagnostic, therapeutic and prognostic
utility.
LMO4 is a member of the LIM-only (LMO) family of
transcription regulators that act as molecular adaptors, providing
a scaffold for multiprotein complexes of DNA-binding factors and
transcriptional regulatory proteins (Rabbitts, 1998; Visvader et al,
2001; Sum et al, 2002, 2005b). Here, we show that aberrant
expression of LMO4 occurs in a significant proportion of PCs and
that low/no LMO4 expression is associated with a poor outcome in
PC. Multivariate analyses identified LMO4 expression as an
independent predictor of survival in this cohort and also in a
subgroup of patients who underwent pancreatic resection. LMO4
expression cosegregated with resectability and was associated with
a significant survival advantage following operative resection.
Thus, LMO4 expression may have potential clinical utility in
estimating prognosis and response to operative resection.
MATERIALS AND METHODS
Patient cohort
We identified a cohort of 120 patients with the diagnosis of
pancreatic ductal adenocarcinoma who underwent pancreatic
resection or biopsy from Westmead Hospital, Concord Hospital,
Royal Prince Alfred Hospital and St Vincent’s Hospital in Sydney,
Australia (Table 1). This cohort represents a subset of a previously
described group of 348 patients (Biankin et al, 2002). Multicentre
ethical approval for data collection and tissue use was granted by
the Human Research Ethics Committees of the above hospitals.
Immunohistochemistry
Pancreatic tissue microarrays were dewaxed and rehydrated before
antigen unmasking, using target retrieval solution (DAKO
Corporation, Carpenteria, CA, USA), in a water bath for 30min.
Endogenous peroxidase activity was quenched with 3% hydrogen
peroxide in methanol, followed by avidin/biotin and serum-free
protein blocks (DAKO Corporation). Rat anti-LMO4 monoclonal
antibody was generated as described previously (Sum et al, 2005a).
Sections were incubated for 30min in anti-LMO4 monoclonal
antibody (20F8) followed by biotinylated rabbit anti-rat IgG
(DAKO Corporation). A streptavidin–biotin–peroxidase system
was used with 3,30-diaminobenzidine as a substrate (DAKO
Corporation). Counterstaining was performed with Mayer’s
hematoxylin (DAKO Corporation).
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Staining was assessed by two separate observers for each case
(DS and JGK), one of whom is a pathologist. Both observers were
blinded to patient identification, clinicopathological variables and
outcome. Standardisation of scoring was achieved by comparison
of scores between observers, and by conferencing, where any
discrepancies were resolved by consensus. For resected specimens,
an average of 3 1.6mm cores were assessed on tissue micro-
arrays; however, due to limitations in tissue availability, only one
or two cores were assessed for biopsy specimens. Scores were given
as percentage of cells with positive nuclear staining within the
representative area of the tissue microarray core and the absolute
intensity of nuclear staining on a scale of 0–3 (0 representing no
staining, 1 representing mild nuclear staining, 2 representing
moderate nuclear staining and 3 representing strong nuclear
staining) (Figure 1A–D). The following criterion was used to
achieve a positive score for LMO4 overexpression: nuclear
intensity X2i n450% of nuclei (Sum et al, 2005b).
Statistical evaluation
Statistical evaluation was performed using the Kaplan–Meier
survival for univariate analysis and the Cox proportional hazards
model for multivariate analysis using the Statview 5.0 software
(Abacus Systems, Berkeley, CA, USA).
Table 1 Clinicopathological and outcome data for all patients in the cohort
Whole cohort n¼120 Resected cohort n¼75
Parameter No. (%) Median survival (months) P-value (log-rank) No. (%) Median survival (months) P-value (log-rank)
Sex
Female 50 (41.7) 30 (40)
Male 70 (58.3) 45 (60)
Age at diagnosis (years)
Mean 64.3 62.3
Median 66.5 65
Range 34.4–83.8 34.4–82.6
Specimen
Resection 75 (62.5) 12.2
Biopsy 39 (32.5) 4.6 o0.0001
Post-mortem 6 (5)
Outcome
Follow-up 0–117.4 0.2–117.4
Median follow-up 7.8 10.8
30-day mortality 2 (2.7)
Death from PC 106 (88.3) 62 (82.6)
Death from other cause 2 (1.7) 2 (2.7)
Alive 8 (6.7) 8 (10.7)
Lost to follow-up 4 (3.3) 3 (4)
Stage
a 119
I 27 (22.7)
II 10 (8.4) 14.8
III 67 (56.3)
IV 15 (12.6) 7.2 0.0001
Differentiation
b 119
Well 9 (7.6) 7 (9.3)
Moderate 65 (54.6) 9.5 44 (58.7) 14.5
Poor 45 (37.8) 6.2 0.0050 24 (32) 9.7 0.0398
Tumour size
p20mm 14 (18.7) 17.1
420mm 61 (81.3) 10.5 0.0455
Margins
Clear 40 (53.3) 16.2
Involved 35 (46.7) 8.6 0.0008
Lymph node status
c 73
Negative 35 (47.9) 16.2
Positive 38 (52.1) 9.7 0.0182
LMO4 status
Negative 20 (16.7) 3.7 9 (12) 6.2
Positive 100 (83.3) 9.2 0.0092 66 (88) 14.2 0.0514
PC¼pancreatic cancer.
aStage I and II vs stage III and IV tumours for survival analysis.
bWell- and moderately differentiated tumours grouped together for survival analysis.
cLymph
node status was only available in 73 patients in the resected cohort.
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LMO4 status
LMO4-negative LMO4 and resection
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P=0.0092 P<0.0001
Median survival: 9.2 vs 3.7 months
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Figure 1 Pancreatic ductal adenocarcinoma: LMO4 nuclear expression score 0–3. (A) 0 representing no staining, (B) 1 representing mild nuclear
staining, (C) 2 representing moderate nuclear staining and (D) 3 representing strong nuclear staining. Kaplan–Meier survival curves for whole cohort:
(E) low/no vs high (450% of nuclei with intensity X2) LMO4 nuclear expression. Effect of resection on prognosis in the following subgroups: (F) LMO4-
positive, (G) LMO4-negative; resected cohort: (H) low/no vs high (450% of nuclei with intensity X2) LMO4 nuclear expression.
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Clinicopathological parameters
Clinicopathological parameters for the cohort are presented in
Table 1.
LMO4 protein expression
Immunohistochemical staining data were analysed in two groups;
initially all patients were analysed, then subsequently only the
subgroup of patients who underwent pancreatic resections.
Significant nuclear LMO4 expression, as defined by the presence
of nuclear staining in 450% of tumour cell nuclei with intensity
X2, was identified in 100 (83.3%) out of 120 tumours (Table 1).
Survival analysis
Kaplan–Meier analysis identified that operative resection of the
tumours, stage 1 and 2 tumours (lymph node negative) and non-
poorly differentiated tumours, was associated with longer survival
(Table 1). Overall disease-specific 1-year survival was 32%, with a
3-year survival of 6% and a 5-year survival of 1%.
Low or no LMO4 expression was associated with a poor outcome
(Figure 1E). Multivariate analysis using Cox proportional hazards
modelling for those factors that were prognostic on univariate
analysis identified LMO4 expression status as an independent
prognostic factor when modelled together with resection, differ-
entiation and Union Internationale Centre le Cancer (UICC) stage
(Table 2, a). This model was refined by stepwise removal of the
redundant variable of differentiation (Table 2, b). Operative
resection was beneficial to patients who expressed LMO4 (median
survival¼14.2 vs 5.0 months, respectively; log-rank: Po0.0001;
Figure 1F); in contrast, those patients whose tumours did not
express LMO4 had no survival advantage over those who
underwent biopsy alone (median survival¼6.2 vs 5.0 months,
respectively; Figure 1G). Hence, in this cohort, LMO4 expression
cosegregated with response to operative resection, with patients
whose tumours were LMO4-negative having no detectable survival
advantage from operative resection.
Resected cohort
Overall disease-specific 1-year survival following resection was
50%, with a 3-year survival of 16% and a 5-year survival of 6%.
Patients in the cohort did not receive chemotherapy as either
primary treatment, or in a neoadjuvant or adjuvant setting.
Chemotherapy of any type was only given to 10 patients for the
palliation of symptoms, and was not associated with a survival
advantage.
Survival analysis of patients who underwent operative resection
identified a trend toward decreased survival with negative LMO4
expression (borderline statistical significance; Figure 1H). Table 2
(c)–(f) shows the multivariate models for resected cancers. The
initial model (Table 2, c) was subjected to stepwise removal
of redundant variables to Table 2 (e), where LMO4 expression
became the only independent prognostic factor. Removal of
margin status demonstrated that LMO4 expression was indepen-
dent of lymph node involvement (Table 2, f); however, LMO4
expression was not independent of margin involvement by the
tumour (Table 2, g).
DISCUSSION
Low or no LMO4 expression was an independent poor prognostic
factor for all patients with PC as well as in the subgroup of patients
who underwent pancreatic resection. Importantly, high LMO4
expression was associated with a significant survival advantage
following operative resection. In contrast, the survival of those
patients whose tumours did not express LMO4 was not
significantly different with resection compared with operative
biopsy alone. Although operative resection is currently the best
method available to treat PC, it is a procedure that carries
significant morbidity and mortality. LMO4 status can potentially
be assessed using preoperative biopsy material without resection
using techniques such as PCR, which overcome the problems of
low tissue yield associated with fine-needle aspirate biopsies. Other
factors such as tumour size, resection margins, perineural invasion
and lymph node status are determined after resection. The ability
to reliably predict which patients will or will not benefit from
surgery would be a significant advance in the treatment of PC.
LMO4 may have a potential role as a marker for determining the
suitability for resection and the prognosis of patients with PC.
Deregulation of LMO4 has been previously described in several
tumour types including breast, prostate and squamous cell
carcinoma of the oral cavity (Visvader et al, 2001; Mousses et al,
2002; Mizunuma et al, 2003). Like the other LMO family members,
LMO4 is a transcriptional cofactor that functions as a scaffold for
the generation of multiprotein complexes (Visvader et al, 2001).
Table 2 Multivariate analysis for clinicopathological parameters and
LMO4 expression in the whole and resected cohorts of PC
Variable
Hazard ratio (95%
confidence interval) P-value
(a) Whole cohort (n¼120)
LMO4 expression 0.535 (0.297–0.961) 0.0364
Operative resection 0.315 (0.191–0.519) o0.0001
Stage I/II vs stage III/IV 1.894 (1.088–3.298) 0.0239
Differentiation 1.252 (0.799–1.962) 0.3275
(b) Whole cohort (n¼120)
LMO4 expression 0.486 (0.279–0.847) 0.0108
Operative resection 0.313 (0.190–0.515) o0.0001
Stage I/II vs stage III/IV 2.024 (1.182–3.466) 0.0102
(c) Resected subgroup (n¼75)
LMO4 expression 0.504 (0.229–1.110) 0.0888
Tumour size 420mm 1.422 (0.697–2.901) 0.3330
Margin involvement 1.575 (0.832–2.981) 0.1629
Lymph node involvement 1.699 (0.912–3.167) 0.0950
Differentiation 1.238 (0.694–2.210) 0.4698
(d) Resected subgroup (n¼75)
LMO4 expression 0.487 (0.223–1.063) 0.0708
Tumour size 420mm 1.439 (0.708–2.933) 0.3144
Margin involvement 1.663 (0.892–3.101) 0.1098
Lymph node involvement 1.721 (0.921–3.215) 0.0887
(e) Resected subgroup (n¼75)
LMO4 expression 0.460 (0.212–0.997) 0.0492
Margin involvement 1.816 (0.990–3.332) 0.0539
Lymph node involvement 1.734 (0.927–3.243) 0.0848
(f) Resected subgroup (n¼75)
LMO4 expression 0.382 (0.180–0.810) 0.0121
Lymph node involvement 2.215 (1.251–3.922) 0.0063
(g) Resected subgroup (n¼75)
LMO4 expression 0.579 (0.282–1.191) 0.1376
Margin involvement 0.426 (0.246–0.737) 0.0023
PC¼pancreatic cancer. A and B, multivariate analysis of the whole cohort, with the
final model (B) following removal of redundant variables. C–G, multivariate analysis
of the resected subgroup. The initial model (C) with stepwise removal of redundant
variables through D to E, where LMO4 expression is the only independent
prognostic factor. Removal of margin status (F) shows that LMO4 expression is
independent of lymph node involvement, but not margin involvement by tumour (G).
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the ubiquitous nuclear adaptor protein Lbd1 (Grutz et al, 1998),
the transcription factor deformed epidermal autoregulatory factor
1 (Sugihara et al, 1998), the basic helix-loop-helix protein HEN1
(Manetopoulos et al, 2003) and the grainyhead-like epithelial
transactivator (Kudryavtseva et al, 2003), as well as the cofactor
CtIP and BRCA1.
In conclusion, current prognostic markers in PCs remain poorly
defined and cannot be determined preoperatively. Assessment of
LMO4 status may provide an additional method for determining
the suitability for resection and the prognosis of patients with PC.
Although this study demonstrates the potential utility of LMO4 as
a prognostic marker for PC, validation of these data is required
in large independent cohorts. Further studies to elucidate the
pathways regulated by LMO4 and mechanisms by which LMO4
contributes to the development and progression of PC will be an
essential step toward further assessing the potential clinical utility
of LMO4 expression levels in PC.
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